| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
Kv1.1 voltage-gated potassium channel.
|
|---|---|
| ln Vitro |
Dendrotoxin K TFA blocks Kv1.1 channels with high selectivity; it controls the release of glutamate into CA3 hippocampal neurons in a time-dependent manner by regulating presynaptic spike waveforms.
|
| ln Vivo |
In vivo, Kv1.1 blockade by Dendrotoxin K alters neuronal excitability and neurotransmitter release; animal studies typically involve direct brain injection or slice electrophysiology rather than systemic administration.
|
| Enzyme Assay |
Electrophysiological patch-clamp assays: Kv1.1 channels are expressed in Xenopus oocytes or HEK293 cells; whole-cell currents are recorded before and after perfusion with 10-100 nM Dendrotoxin K; block is assessed by current reduction.
|
| Cell Assay |
Primary neuronal cultures or heterologous cells expressing Kv1.1 are exposed to Dendrotoxin K at 1-100 nM; membrane potential changes or glutamate release are measured by fluorescent dyes or electrochemical detection.
|
| Animal Protocol |
Brain slices containing the hippocampus are prepared; Dendrotoxin K is applied via bath perfusion (50-200 nM) to CA3 neurons; presynaptic spike waveform and glutamate release are recorded by whole-cell patch clamp.
|
| ADME/Pharmacokinetics |
PK data are not available; as a protein/peptide toxin, Dendrotoxin K is not orally bioavailable and is typically used ex vivo in electrophysiology experiments rather than systemic administration.
|
| Toxicity/Toxicokinetics |
No toxicity studies are available; as a specific Kv1.1 blocker, neurotoxicity (seizures, neuronal hyperexcitability) would be expected at high doses; appropriate safety precautions should be taken.
|
| References | |
| Additional Infomation |
Dendrotoxin K is a neurophysiology research tool; it has no clinical trial status or therapeutic approval.
|
| Molecular Formula |
C294H462N84O75S6.XC2HF3OC2
|
|---|---|
| Molecular Weight |
6559.66 (free base)
|
| Related CAS # |
Dendrotoxin K;119128-61-9
|
| Appearance |
White to off-white solid powder
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
